Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov;6(Suppl 1):S27.
doi: 10.21037/atm.2018.09.31.

Surrogate study endpoints in the era of cancer immunotherapy

Tsuyoshi Hamada  1   2 , Keisuke Kosumi  2   3 , Yousuke Nakai  1 , Kazuhiko Koike  1
Affiliations
Editorial

Surrogate study endpoints in the era of cancer immunotherapy

Tsuyoshi Hamada et al. Ann Transl Med. 2018 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Surrogate study endpoints for overall survival in clinical trials testing immune checkpoint inhibitors.
Figure 2
Figure 2
Results of correlation tests between study endpoints (17). (A) Correlations of differences in endpoints between treatment arms (analyses at the trial level); (B) correlations of endpoints within treatment arms (analyses at the treatment-arm level). HR, hazard ratio; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; r, correlation coefficient.
See this image and copyright information in PMC

Comment on

References

    1. Bellera CA, Pulido M, Gourgou S, et al. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. Eur J Cancer 2013;49:769-81. 10.1016/j.ejca.2012.09.035 - DOI - PubMed
    1. Hamada T, Nakai Y, Isayama H, et al. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Eur J Cancer 2016;65:11-20. 10.1016/j.ejca.2016.05.016 - DOI - PubMed
    1. Tang PA, Bentzen SM, Chen EX, et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25:4562-8. 10.1200/JCO.2006.08.1935 - DOI - PubMed
    1. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24. 10.1200/JCO.2007.11.8836 - DOI - PubMed
    1. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology 2006;7:741-6. 10.1016/S1470-2045(06)70800-2 - DOI - PubMed